Economic Burden of Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) in the US

被引：0
|
作者：
Aly, Abdalla
Bapat, Bela
Ray, Saurabh
Chen, Zhiyong
Botteman, Marc
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3386
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Machine learning applications to optimize dosimetric imaging of I131-apamistamab for bone marrow conditioning in relapsed/refractory acute myeloid leukemia (R/R AML)
    Brodin, Patrik
    Schwartz, Jazmin
    Wang, Weiqing
    Spross, Jennifer
    Pandit-Taskar, Neeta
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [22] A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
    Daver, Naval
    Assi, Rita
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Jabbour, Elias
    DiNardo, Courtney D.
    Kadia, Tapan M.
    Ning, Jing
    Nogueras-Gonzalez, Graciela
    Pierce, Sherry
    Gombos, Dan
    Komblau, Steven
    Konopleva, Marina
    Kelly, Mary
    Borthakur, Gautam
    Zhang, Weiguo
    Cortes, Jorge
    Kantarjian, Hagop
    Andreeffl, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S7 - S8
  • [23] ECONOMIC BURDEN OF ACUTE MYELOID LEUKEMIA RELAPSE IN US PATIENTS
    Potluri, R.
    Papademetriou, E.
    Kiendrebeogo, Z. N.
    Liu, X.
    Chen, C.
    VALUE IN HEALTH, 2022, 25 (07) : S388 - S388
  • [24] HUMANISTIC BURDEN OF NEWLY DIAGNOSED VERSUS RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
    Panjabi, S.
    Bychenkova, A.
    McCloskey, C.
    Nair, S.
    Price, K.
    Yucel, E.
    VALUE IN HEALTH, 2019, 22 : S500 - S500
  • [25] Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database
    Bhavik J. Pandya
    Chi-Chang Chen
    Bruno C. Medeiros
    Catherine B. McGuiness
    Samuel Wilson
    L. Elise Horvath Walsh
    Rolin L. Wade
    Advances in Therapy, 2019, 36 : 1922 - 1935
  • [26] Economic and Clinical Burden of Relapsed and/or Refractory Active Treatment Episodes in Patients with Acute Myeloid Leukemia (AML) in the USA: A Retrospective Analysis of a Commercial Payer Database
    Pandya, Bhavik J.
    Chen, Chi-Chang
    Medeiros, Bruno C.
    McGuiness, Catherine B.
    Wilson, Samuel
    Walsh, L. Elise Horvath
    Wade, Rolin L.
    ADVANCES IN THERAPY, 2019, 36 (08) : 1922 - 1935
  • [27] Gemtuzumab Ozogamicin Containing Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Children
    Liu, Anthony Pak-Yin
    Leung, Alex Wing-Kwan
    Cheuk, Daniel Ka-Leung
    Lee, Vincent
    Ha, Shau-Yin
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2018, 40 (02) : 163 - 168
  • [28] Efficacy of treatments in children with relapsed/refractory acute lymphocytic leukemia (r/r ALL)
    Martin, Amber L.
    Thomas, Simu K.
    Cota, Mariana
    Hao, Yanni
    Zhang, Younan
    Turner, Monica
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] Burden of acute myeloid leukemia (AML) in a US commercially insured population.
    Hagiwara, May
    Sharma, Arati
    Chung, Karen C.
    Delea, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] VENETOCLAX PLUS HYPOMETHYLATING AGENTS (HMAS) FOR RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) IS AN EFFECTIVE AND MANAGEABLE REGIMEN IN THE OUTPATIENT SETTING: A REAL-LIFE EXPERIENCE
    Nanni, J.
    Papayannidis, C.
    Cristiano, G.
    Marconi, G.
    Sartor, C.
    Parisi, S.
    Ottaviani, E.
    Bandini, L.
    Testoni, N.
    Baldazzi, C.
    Ricci, P.
    Bezzi, C. Di Giovanni
    Abd-Alatif, R.
    Paolini, S.
    Cavo, M.
    Curti, A.
    HAEMATOLOGICA, 2020, 105 : S94 - S94
12345